{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:21:00Z","timestamp":1783578060510,"version":"3.55.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Telavancin had MIC\n            <jats:sub>50<\/jats:sub>\n            , MIC\n            <jats:sub>90<\/jats:sub>\n            , and MIC\n            <jats:sub>100<\/jats:sub>\n            values of 0.03, 0.06, and 0.12 \u03bcg\/ml, respectively, against methicillin-susceptible\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            , methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            (MRSA), and non-multidrug-resistant (non-MDR) and MDR subsets. MRSA with elevated MIC values for vancomycin (2 to 4 \u03bcg\/ml) or daptomycin (1 to 2 \u03bcg\/ml) had telavancin MIC\n            <jats:sub>50<\/jats:sub>\n            (0.06 \u03bcg\/ml) values 2-fold higher than those of isolates with lower MIC results (MIC\n            <jats:sub>50<\/jats:sub>\n            , 0.03 \u03bcg\/ml). However, telavancin had MIC\n            <jats:sub>90<\/jats:sub>\n            and MIC\n            <jats:sub>100<\/jats:sub>\n            results of 0.06 and 0.12 \u03bcg\/ml (100% susceptible), respectively, regardless of the MRSA subset.\n          <\/jats:p>","DOI":"10.1128\/aac.04616-14","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T03:55:44Z","timestamp":1420516544000},"page":"1811-1814","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":23,"title":["Telavancin\n            <i>In Vitro<\/i>\n            Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States"],"prefix":"10.1128","volume":"59","author":[{"given":"Rodrigo E.","family":"Mendes","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit614"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S37071"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir308"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02024-12"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/499815"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/528716"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir935"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir270"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid\/1706.101037"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2014.931596"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080434"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq028"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00011-12"},{"key":"e_1_3_2_16_2","unstructured":"Theravance. 2014. Vibativ package insert. http:\/\/www.vibativ.com."},{"key":"e_1_3_2_17_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 24th informational supplement M100-S24","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing: 24th informational supplement M100-S24. Wayne, PA."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03172-14"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02411-06"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01513-07"},{"key":"e_1_3_2_21_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A9: ninth edition","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A9: ninth edition. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_22_2","unstructured":"EUCAST. 2014. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0 January 2014. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 2 January 2014."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1220"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.09.017"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04616-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04616-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:52:50Z","timestamp":1645483970000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.04616-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1128\/AAC.04616-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.04616-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"2014-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}